Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866603 | 0.88 | MAP3K5 (0.53) | WEE1PTK2GSK3AGSK3BSYK | |
| SCHEMBL3867205 | 0.87 | PTK2 (0.45) | WEE1PTK2CYP17A1KITJAK3 | |
| SCHEMBL4413379 | 0.86 | PTK2 (0.44) | WEE1PTK2GSK3AGSK3BKIT | |
| SCHEMBL5583794 | 0.82 | EGFR (0.50) | WEE1PTK2KITMAPK14MET | |
| SCHEMBL4414503 | 0.76 | RIPK2 (0.49) | WEE1PTK2GSK3AGSK3BSYK | |
| SCHEMBL3865121 | 0.76 | STAT6 (0.53) | SYK | |
| SCHEMBL3860345 | 0.74 | MAP3K5 (0.56) | WEE1KITJAK3MAPK14 | |
| SCHEMBL6027799 | 0.74 | WEE1 (0.42) | WEE1PTK2GSK3AGSK3BSYK | |
| SCHEMBL4416886 | 0.73 | MAP3K5 (0.55) | WEE1KITJAK3MAPK14 | |
| SCHEMBL3867128 | 0.73 | RXFP1 (0.44) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550589-B2 | 6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20070259899-A1 | 6-(2-Alkyl-Phenyl)-Pyrido[2,3-D]Pyrimidines useful as Proteine Kinase Inhibitors | HOFFMANN-LA ROCHE INC. | 2007-11-08 | — | — | US | claimed |
| EP-1794160-A1 | 6-(2-ALKYL-PHENYL) - PYRIDO[2,3-D] PYRIMIDINES USEFUL AS PROTEINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032452-A1 | 6-(2-ALKYL-PHENYL) - PYRIDO[2,3-D] PYRIMIDINES USEFUL AS PROTEINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-20090247518-A1 | 6-(2-ALKYL-PHENYL)-PYRIDO[2,3-D]PYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | HONOLD KONRAD | 2009-10-01 | — | — | US | disclosed |
| US-7550589-B2 | 6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070259899-A1 | 6-(2-Alkyl-Phenyl)-Pyrido[2,3-D]Pyrimidines useful as Proteine Kinase Inhibitors | HOFFMANN-LA ROCHE INC. | 2007-11-08 | — | — | US | disclosed |
| EP-1794160-A1 | 6-(2-ALKYL-PHENYL) - PYRIDO[2,3-D] PYRIMIDINES USEFUL AS PROTEINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032452-A1 | 6-(2-ALKYL-PHENYL) - PYRIDO[2,3-D] PYRIMIDINES USEFUL AS PROTEINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | WEE1 531/4885PTK2 2008/4885SLC22A12 3488/4885 |
| US-20090247518-A1 | 6-(2-ALKYL-PHENYL)-PYRIDO[2,3-D]PYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP3K6, MAP3K1 | WEE1 835/4885PTK2 229/4885SLC22A12 4805/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | WEE1 755/4885PTK2 1851/4885SLC22A12 3869/4885 |
| US-20070259899-A1 | 6-(2-Alkyl-Phenyl)-Pyrido[2,3-D]Pyrimidines useful as Proteine Kinase Inhibitors | MAP3K6, MAP4K2, CDK2 | WEE1 504/4885PTK2 230/4885SLC22A12 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.